New Research Reveals Limitations of Xeruborbactam in Treating Pseudomonas Aeruginosa

Strategic Insights -

Researchers from the Vietnamese-German Centre for Medical Research have conducted a study evaluating the effectiveness of cefiderocol in combination with either taniborbactam or xeruborbactam against cefiderocol-resistant Pseudomonas aeruginosa isolates from Vietnam and Nigeria. The study found that taniborbactam restored cefiderocol susceptibility in 20 out of 21 isolates (95.2%), while xeruborbactam had no effect. The researchers concluded that these findings highlight the species-specific limitations of xeruborbactam in treating Pseudomonas aeruginosa.

Key Takeaways:

  • The study involved 21 cefiderocol-resistant Pseudomonas aeruginosa isolates from Vietnam and Nigeria.
  • Taniborbactam restored cefiderocol susceptibility in 20 out of 21 isolates (95.2%), while xeruborbactam had no effect.
  • The study revealed that xeruborbactam has limited effectiveness in treating Pseudomonas aeruginosa.
  • Resistance to cefiderocol was reversed by dipicolinic acid, suggesting New-Delhi Metallo-b-Lactamase (NDM)-mediated resistance.
  • One isolate that was unresponsive to taniborbactam carried multiple copies of the resistance gene.

Statistics:

  • 21 cefiderocol-resistant Pseudomonas aeruginosa isolates were studied.
  • 20 out of 21 isolates (95.2%) were restored to cefiderocol susceptibility by taniborbactam.
  • Xeruborbactam had no effect on the isolates.

Sources:

  • "Efficacy of cefiderocol in combination with xeruborbactam versus taniborbactam against cefiderocol-resistant NDM-producing Pseudomonas aeruginosa." Antimicrobial Agents and Chemotherapy, 2025.
  • Truong Nhat My, Vietnamese-German Centre for Medical Research (VG-CARE), Hanoi, Vietnam.
  • Kaan Kocer, Bui Tien Sy, Lisa Gopel, Thirumalaisamy P. Velavan, Le Huu Song, Silke Peter, Sebastien Boutin, Adesola Olalekan, and Dennis Nurjadi.
  • Amer Soc Microbiology, 1752 N St NW, Washington, DC 20036-2904, USA.
  • NewsRx. Studies from Truong Nhat My and Co-Researchers in the Area of Pseudomonas aeruginosa Reported (Efficacy of cefiderocol in combination with xeruborbactam versus taniborbactam against cefiderocol-resistant NDM-producing Pseudomonas aeruginosa). Life Science Weekly. October 21, 2025; p 7251.